The methodological figure of the experimental steps. by Railson de Oliveira Ferreira (6493700)

A decrease in circulating CXCR5+CD4+ Tfh cells is associated with HCC progression, and CXCR5+CD4+ Tfh cells are decreased in tumor regions. by Yiqiong Jia (692871)

“…<p>(A) The prevalence of CXCR5+CD4+ Tfh cells decreases with progressive stages in HCC. …”

Decreasing the use of edible oils in China using WeChat and theories of behavior change: study protocol for a randomized controlled trial. by Zhu, Rui

“…Described by Forbes as one of the world's most powerful apps, WeChat provides considerable convenience in disseminating knowledge. …”
Get full text
Get full text

Increased expression of Fz5 receptor matched with a decrease in NeuN immunoreactivity at 16w. by Carlos González-Fernández (2794207)

MeV disrupted mitochondrial network and cellular metabolism. by Pierre Khalfi (7868252)

Subjects:

<i>Zip88E</i>^<i>Δ/Δ</i> larvae have decreased <i>MtnB</i>:<i>EYFP</i> expression. by Christopher D. Richards (4246669)

“…<p>A, B, D, E) <i>MtnB</i>:<i>EYFP</i> expression in third instar larval midguts from control and <i>Zip88E</i>^<i>Δ/Δ</i> homozygous larvae on basal medium (A and B) and after exposure to 2 mmol l^-1 ZnCl₂-supplemented medium (D, E). …”

The synchronous activity of SGN fiber populations is disrupted and their response to sound is decreased with increasing levels of <i>L</i>_<i>u</i> heterogeneity. by Maral Budak (6680351)

Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

“…At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”

Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

“…At baseline, patients displayed overhydration (OH) with + 0.4 (-0.2 – 2.2) L/1.73m² which decreased by 0.5 (0.1 – 1.2) L/1.73m² after 6 months. …”

Tetrahydrohyperforin Inhibits the Proteolytic Processing of Amyloid Precursor Protein and Enhances Its Degradation by Atg5-Dependent Autophagy by Viviana A. Cavieres (500139)

“…We show herein that IDN5706 decreases the levels of ER degradation enhancer, mannosidase alpha-like 1 (EDEM1), a key chaperone related to endoplasmic-reticulum-associated degradation (ERAD). …”

Table_2_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx by Lenin Domínguez-Ramírez (481547)

“…<p>Mexico, one of the countries severely affected by COVID-19, accumulated more than 5. 1 all-cause excess deaths/1,000 inhabitants and 2.5 COVID-19 confirmed deaths/1,000 inhabitants, in 2 years. …”

Investigating the shared genetics of non-syndromic cleft lip/palate and facial morphology by Laurence J. Howe (5579186)

“…Across 5,804 individuals of European ancestry from two studies, we found strong evidence, using PRS, of genetic overlap between nsCL/P and philtrum width; a 1 S.D. increase in nsCL/P PRS was associated with a 0.10 mm decrease in philtrum width (95% C.I. 0.054, 0.146; P = 2x10^-5). …”

Supplementary Data from Increased frequency of travel in the presence of cross-immunity may act to decrease the chance of a global pandemic by R. N. Thompson (6480983)

Genetic information on 5 subjects carrying <i>NR5A1</i> mutations. by Jana Malikova (615672)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Interpretation of bidirectional MR. by Laurence J. Howe (5579186)